While Maria was receiving chemoimmunotherapy, genomic testing was performed and revealed that Maria carried a relatively rare genetic mutation on the BARD1 gene. This suggested that her cancer ...

In this study, we report that the BARD1 Cys557Ser variant confers risk of breast cancer and that the risk extends to carriers of the Icelandic BRCA2 999del5 mutation. Carriers of the Cys557Ser ...

Dr Irmgard Irminger-Finger is the founder and co-inventor of BARD1 Life Sciences and its technology. She has more than 15 years of experience in biotech as founder, director, chair, recipient of Swiss ...

The vulnerability was a mutation in the BARD1 gene, causing a defect in a DNA damage repair pathway. PARP inhibition, in combination with chemotherapeutics, exploited the cancer's DNA damage ...

Olaparib monotherapy demonstrates clinical benefit despite use in later lines of therapy in a real-world study of patients with mCRPC and human recombinant repair gene mutations. Several lines of ...

One notable study where high-speed AFM with the NanoRacer provided novel insights into a biological system's dynamics is the investigation of the BRC-BARD1 protein complex involved in DNA repair. This ...

The researchers looked at 11 cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MSH6, PALB2, RAD51C, and RAD51D) for any association between pathogenic gene variants and DCIS.

His team’s new work moves researchers closer to that goal. Because BRCA1 can’t function if it cannot bind to BARD1, the team was able to use the results of this lab test to score the likelihood that ...

Unusual prevalence of cancer genetic mutations in a cohort of predominantly non-Caucasian cancer patients. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not ...

The BARD1 Life Sciences Limited (ASX: BD1) share price isn't going anywhere on Thursday. In fact, the BARD1 share price has vanished completely from the ASX boards today. Where is the BARD1 share ...

Under its Merchant Opportunities Fund, the group has backed the likes of PolyNovo, Bard1 Life Sciences, Medical Developments and Race Oncology. Since Merchant took over the fund (it was formerly ...

Using advanced imaging technology, Mayo Clinic scientists have provided a better understanding of the BRCA1-BARD1 protein complex, which is often mutated in patients with breast or ovarian cancer.